Breast Cancer Stage IV Clinical Trial
Official title:
A Phase Ib/II Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer
This research study is studying a drug called Palbociclib in combination with Bazedoxifene (a type of endocrine therapy, which prevents breast cancer cell growth by blocking estrogen stimulation) as a possible treatment for this diagnosis. The names of the study interventions involved in this study are: - Palbociclib - Bazedoxifene
This research study is a Phase I/II clinical trial. Phase II clinical trial tests the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied. It also means that the FDA (the U.S. Food and Drug Administration) has not yet approved Palbociclib in combination with Bazedoxifene for use in participants with your type of cancer, but it has been approved for other uses (metastatic breast cancer). Palbociclib is a drug that may stop cancer cells from growing. Palbociclib blocks activity of two closely related enzymes (proteins that help chemical reactions in the body occur), called Cyclin D Kinases 4 and 6 (CDK 4/6). These proteins are part of a pathway, or a sequence of steps which is known to control cell growth. Laboratory testing has shown that palbociclib may stop the growth of hormone receptor positive breast cancer. Endocrine therapy prevents breast cancer cell growth by blocking the activity of the estrogen receptor. During this study the endocrine therapy will be bazedoxifene. In this research study, the investigators are evaluating how safe palbociclib is and how well palbociclib in combination with bazedoxifene, a form of endocrine treatment, works in participants with a history of stage four breast cancer. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04469127 -
A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer Patients.
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
Withdrawn |
NCT04123704 -
Sitravatinib in Metastatic Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05377047 -
Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer
|
N/A | |
Completed |
NCT03304210 -
PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer
|
Phase 1 | |
Completed |
NCT05054374 -
A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05559528 -
BRaziLian outcomE for metAStatic breasT Cancer
|
||
Active, not recruiting |
NCT05090358 -
Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05033925 -
Ficus Septica Leaves Fraction as a Complementary Therapy for Stadium IV Breast Cancer Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT03401359 -
The Resistance and Immune Response to Palbociclib in Breast Cancer
|
N/A | |
Active, not recruiting |
NCT03870919 -
Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients
|
N/A | |
Not yet recruiting |
NCT05860907 -
Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis
|
Phase 4 | |
Completed |
NCT00393341 -
Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer
|
N/A | |
Recruiting |
NCT05625087 -
Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib
|
Phase 2 | |
Completed |
NCT04566458 -
RWD Study in HER2+ mBC Patients in Third-Line Therapy
|
||
Recruiting |
NCT06075810 -
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04697043 -
The Benefit of Surgery in Stage IV of Breast Cancer
|
N/A | |
Recruiting |
NCT05837533 -
Multicenter Study to Evaluate a Systematized Communication Model for Breast Cancer Patients
|
N/A | |
Active, not recruiting |
NCT03324425 -
Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05670054 -
Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients
|
Phase 3 |